WO1998020044A1 - Acylated cyclodextrin derivatives - Google Patents
Acylated cyclodextrin derivatives Download PDFInfo
- Publication number
- WO1998020044A1 WO1998020044A1 PCT/US1997/018105 US9718105W WO9820044A1 WO 1998020044 A1 WO1998020044 A1 WO 1998020044A1 US 9718105 W US9718105 W US 9718105W WO 9820044 A1 WO9820044 A1 WO 9820044A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- composition
- drug
- percent
- polypeptide
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre
Definitions
- cyclodextnns as cyclic oligosaccharides .
- the a , ⁇ , and ⁇ -cyclodextnns which consist of six, seven, and eight glucose units, respectively, are the most common natural cyclodextnns .
- Cyclodextnns have been used as inclusion complexes by complexmg with a guest compound or molecule as a host compound or molecule. Such inclusion complexes have been used to mask the bitter taste or unpleasant odor of a guest compound, to solubilize a hardly soluble guest compound, to enlarge the stability of a guest compound against heat, light, or air, to stabilize emulsions, or as a sustained release preparation using a hydrophobic alkylated cyclodextrin. See U.S. Patent No. 4,869.904. However, no one has attempted to make carboxyacylated cyclodextnns, or used such cyclodextrin derivatives to form ionic sustained release compositions.
- the present invention features a cyclodextrin derivative, wherein at least 60 (e.g., between 75 and 100) percent of the free hydroxy groups of the cyclodextrin are acylated with acyl groups where at least one of the acyl groups comprises a free carboxylic group.
- cyclodextrin is a cyclic oligosaccharide .
- Examples of cyclodextnns include a- cyclodext ⁇ n, 3-cyclodextrm, or ⁇ -cyclodext ⁇ n.
- the acyl groups are selected from COE ⁇ where E ⁇ is selected from the group consisting of C 2 32 carboxy alkyl , C 3 33 carboxy alkenyl, C 737 carboxyaryl , C 838 carboxyaryl alkyl , and C 939 carboxyaryl alkenyl, and COE 2 , where E 2 is selected from the group consisting of C x 30 alkyl, C 230 alkenyl, C 636 aryl , C 737 arylalkyl, and C 8 _ 38 arylalkenyl, wherein at least one of the acyl group is .
- the invention features a copolymer comprising the cyclodextrin derivative described above, wherein the cyclodextrin derivative comprises at least one free hydroxy group which is acylated with a polyester comprising hydroxy acid monomers.
- the copolymer has an average molecular weight of between 500 - 40,000 daltons (e.g., 500 - 10,000).
- the polyester comprises hydroxy acid monomers selected from the group consisting of lactic acid, glycolic acid, hydroxy caprolic acid, or any optically active isomer thereof.
- polyesters can be manufactured by reacting said cyclodextrin derivative with lactide, glycolide, caprolactone, p-dioxanone, trimethyl carbonate, or any optically active isomer thereof.
- the invention features a composition comprising the cyclodextrin derivative described above and a drug, the drug comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of the polypeptide present in the composition is ionically bonded to the cyclodextrin derivative.
- the composition comprises between 1 and 30 (e.g., between 10 and 20) percent, by weight, of the drug.
- the drug is a polypeptide.
- the polypeptide comprises between 4 and 200 amino acids (e.g., between 4 and 50 ammo acids) .
- the polypeptide include somatostatm, bombesm, calcitonm, amylm, parathyroid hormone, parathyroid hormone related protein, gast ⁇ n releasing peptide, lutemizmg hormone releasing hormone, growth hormone, growth hormone releasing factor, terferons, erythropoietm, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, pituitary adenylate cyclase activating polypeptide, vasoactive intestinal peptide, thyrotropm releasing hormone, corticotrop releasing hormone, Acetyl-Ser-Asp-Lys-Pro, argmme vasopressm, angiotensm, and any fragments, agonists, or antagonists thereof.
- the invention features a composition comprising the copolymer described above and a drug, the drug comprising at least one effective lonogenic am e, wherein at least 50 percent, by weight, of the polypeptide present in the composition is lonically bonded to the cyclodextrin derivative.
- the composition comprises between 1 and 30
- the drug is a polypeptide .
- lower alkyl is intended to include both branched and straigh -chain saturated aliphatic hydrocarbon groups.
- Examples of lower alkyl groups include methyl, ethyl, propyl , isopropyl, butyl, t-butyl, isobutyl, sec-butyl, and the like.
- Lower alkenyl include those branched and straight chain aliphatic hydrocarbon groups having one or several double bonds.
- alkenyl groups include vinyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl , 1-propenyl, 2- butenyl , 2 -methyl -2 -butenyl , isoprenyl, and the like. All alkyl, alkenyl, and alkynyl groups are noncyclic.
- aryl is intended to include any stable monocyclic, bicyclic, or t ⁇ cyclic carbon rmg(s) of up to 7 members m each ring, wherein at least one ring is aromatic.
- aryl groups include phenyl, naphthyl , anthracenyl, biphenyl, tetrahydronaphthyl, mdanyl, phenanthreynl, and the like.
- carboxy is meant to include the recited chemical group (e.g., alkyl, alkenyl, aryl, arylalkyl, arylalkenyl) substituted with 1 to 3 carboxy groups.
- Cyclodextrin (Amaizo, American Maize Products Corp. Hammond, IN) was dried at 90 °C under reduced pressure (0.1 mm Hg) to a constant weight. Dried cyclodextrin (CD) was then transferred to a reaction flask equipped for stirring. After purging with argon, the CD was heated at 50°C for 30 mm. at 0.1 mm Hg, cooled to 25 °C, and repurged with dry argon. Calculated amount of the acylating reagent, as a liquid anhydride (except in ADC No.
- the resulting precipitate was filtered, rinsed several times with cold water, and air dried. The product was then isolated and dried until constant weight under vacuum, first at 25°C and then 50°C. The product was characterized for equivalent weight, as reported in Table I, by measuring titratable carboxylic acid functionally using benzyl alcohol solution of the product and potassium hydroxide in benzyl alcohol with bromophenol red as an indicator.
- CD is ⁇ -Cyclodextrin
- A is Acetic Anhydride
- P is Propionic Anhydride
- B is Butyric Anhydride
- S is Succinic Anhydride
- G Gluta ⁇ c Anhydride
- Example 2 Grafting Acylated Cyclodextrin (G-ACD) with Lactones
- G-ACD acylated Cyclodextrin derivative
- ACD acylated cyclodextrin derivative
- lactone or mixture of lactones a catalytic amount (i.e., ⁇ 0.2 percent by weight) of stannous octoate
- a catalytic amount i.e., ⁇ 0.2 percent by weight
- the amount of ACD and lactones used are described m Table II.
- the mixture was then heated under vacuum at about 45°C for 30 min. , cooled to room temperature, and then purged with dry argon.
- the reactants were then heated while stirring as described Table II.
- G is glycolide
- L is D,L-Lactide
- CL is e -Caprolactone
- acylated ⁇ - cyclodextrin (ACD) was dissolved in a minimum volume of acetone (from 5-15 weight/volume percent) and filtered through a micro-syringe with 0.45 ⁇ m porous filter. The filtrate was cooled and a IN sodium hydroxide aqueous solution was added to neutralize carboxylic groups in the ACD.
- the weight of the dried composition was determined, and the composition was characterized for percent content of peptide, as measured by elemental analysis of the percent of nitrogen present in the composition (Quantitative Technologies, Inc., Whitehouse, NJ) , as reported in Table III.
- the particulate product was reduced in size by grinding to achieve an average particle size of about 100 ⁇ before storage under reduced pressure.
- G-ACD grafted ACD
- both the ungrafted composition U-CON- 19 and the grafted composition U-CON- 16 released the drug LanreotideTM over a period of at least 22 days.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12965297A IL129652A0 (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives |
JP52139498A JP2001503802A (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivative |
NZ335387A NZ335387A (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives used as inclusion complexes to mask the bitter taste or odour, solubilize hardly soluble compounds or stabilise compounds |
CA002269519A CA2269519C (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives |
DK97910005T DK0935613T3 (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives |
EP97910005A EP0935613B1 (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives |
AU47483/97A AU728398B2 (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives |
AT97910005T ATE219109T1 (en) | 1996-11-01 | 1997-10-06 | ACYLATED CYCLODEXTRINE DERIVATIVES |
DE69713369T DE69713369T2 (en) | 1996-11-01 | 1997-10-06 | ACYLATED CYCLODEXTRIN DERIVATIVES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/740,778 US5916883A (en) | 1996-11-01 | 1996-11-01 | Acylated cyclodextrin derivatives |
US08/740,778 | 1996-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998020044A1 true WO1998020044A1 (en) | 1998-05-14 |
Family
ID=24978025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/018105 WO1998020044A1 (en) | 1996-11-01 | 1997-10-06 | Acylated cyclodextrin derivatives |
Country Status (13)
Country | Link |
---|---|
US (2) | US5916883A (en) |
EP (1) | EP0935613B1 (en) |
JP (1) | JP2001503802A (en) |
AT (1) | ATE219109T1 (en) |
AU (1) | AU728398B2 (en) |
CA (1) | CA2269519C (en) |
DE (1) | DE69713369T2 (en) |
DK (1) | DK0935613T3 (en) |
ES (1) | ES2176705T3 (en) |
IL (1) | IL129652A0 (en) |
NZ (1) | NZ335387A (en) |
PT (1) | PT935613E (en) |
WO (1) | WO1998020044A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000026501A (en) * | 1998-07-10 | 2000-01-25 | Daicel Chem Ind Ltd | Acetylated nitrocellulose and its production |
WO2002080910A1 (en) * | 2001-04-10 | 2002-10-17 | Universidade Federal De Minas Gerais-Ufmg | Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
US7786095B2 (en) | 2000-04-28 | 2010-08-31 | University College Dublin | Amphiphilic macrocyclic derivatives and their analogues |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1286510B1 (en) * | 1996-11-29 | 1998-07-15 | Cooperativa Centro Ricerche Po | BUTYRIC ESTERS WITH ANTI-PROLIFERATIVE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
CZ303120B6 (en) | 1998-12-07 | 2012-04-11 | Societe De Conseils De Recherches Et Dapplications Scientifiques S. A. | Compound and pharmaceutical composition |
US6566556B2 (en) * | 2000-12-19 | 2003-05-20 | Nippon Shokubai Co., Ltd. | Method for production of alkanolamine and apparatus therefor |
BRPI0105509B8 (en) * | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulations of the angiotensin- (1-7) peptide using cyclodextrins, liposomes and the plga polymer |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
US7122622B2 (en) * | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
US6709746B2 (en) * | 2002-06-05 | 2004-03-23 | Arteva North America S.á.r.l. | Reducing concentration of organic materials with substituted cyclodextrin compound in polyester packaging materials |
MXPA05004721A (en) * | 2002-10-31 | 2005-08-03 | Pfizer Prod Inc | Solid and semi-solid polymeric ionic conjugates. |
CA2504345A1 (en) * | 2002-10-31 | 2004-05-13 | Pfizer Products Inc. | Liquid conjugates of solid pharmaceuticals |
US7385004B2 (en) * | 2002-12-10 | 2008-06-10 | Cellresin Technologies, Llc | Enhanced lubrication in polyolefin closure with polyolefin grafted cyclodextrin |
US7166671B2 (en) * | 2002-12-10 | 2007-01-23 | Cellresin Technologies, Llc | Grafted cyclodextrin |
US8129450B2 (en) | 2002-12-10 | 2012-03-06 | Cellresin Technologies, Llc | Articles having a polymer grafted cyclodextrin |
SE0303179D0 (en) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
ES2393335T3 (en) | 2003-12-16 | 2012-12-20 | Ipsen Pharma | GLP-1 analogues |
EP1753817B1 (en) * | 2004-05-24 | 2010-09-08 | Cellresin Technologies, LLC | Amphoteric grafted barrier materials |
EP1915167A4 (en) | 2005-07-08 | 2010-04-07 | Ipsen Pharma | Melanocortin receptor ligands |
CN101253219B (en) * | 2005-08-31 | 2012-10-31 | 日产自动车株式会社 | Hydrophobic modified polyrotaxane and crosslinked polyrotaxane |
MX2009011619A (en) | 2007-04-27 | 2010-01-18 | Cydex Pharmaceuticals Inc | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use. |
US20090060860A1 (en) * | 2007-08-31 | 2009-03-05 | Eva Almenar | Beta-cyclodextrins as nucleating agents for poly(lactic acid) |
EP2650006A1 (en) | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
AU2008325194B2 (en) | 2007-11-05 | 2012-04-19 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use melanocortins to treat insulin sensitivity |
RU2509809C2 (en) | 2008-07-04 | 2014-03-20 | Транслэшионал Кэнсэр Драгз Фарма, С.Л. | Methods of treating and diagnosing cancer |
CA2733006A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal |
AU2009280012B2 (en) | 2008-08-07 | 2012-12-06 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
WO2010016940A2 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
US20110293562A1 (en) | 2009-02-12 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Use of cardiotrophin-1 for the treatment of metabolic diseases |
WO2010132711A1 (en) | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
ES2767880T3 (en) | 2009-05-29 | 2020-06-18 | Cydex Pharmaceuticals Inc | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of preparing and using them |
US8759299B2 (en) | 2009-07-22 | 2014-06-24 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59 |
JP6154163B2 (en) * | 2013-03-15 | 2017-06-28 | 独立行政法人国立高等専門学校機構 | Water-insoluble cyclodextrin polymer and process for producing the same |
CN105561330B (en) * | 2016-01-25 | 2018-05-25 | 四川大学 | A kind of human calcitonin-Cucurbituril compound formulation and preparation method thereof |
CN112759667A (en) * | 2021-01-05 | 2021-05-07 | 淄博千汇生物科技有限公司 | Preparation method of triacetyl-beta-cyclodextrin |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3453260A (en) * | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclic anhydride esters of cyclodextrin |
GB2145422A (en) * | 1983-08-26 | 1985-03-27 | Sandoz Ltd | Novel poly-esters, their preparation and pharmacological use thereof |
US4670419A (en) * | 1982-07-28 | 1987-06-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its rectal use |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426011A (en) * | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US4659696A (en) | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
JPH0819004B2 (en) * | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | Sustained-release pharmaceutical preparation |
US5658894A (en) * | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
US5183809A (en) * | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5247013A (en) * | 1989-01-27 | 1993-09-21 | Mitsui Toatsu Chemicals, Inc. | Biocompatible polyester and production thereof |
DE69127256T2 (en) * | 1990-05-21 | 1998-02-12 | Toppan Printing Co Ltd | CYCLODEXTRIN DERIVATIVE |
CA2066616A1 (en) * | 1990-10-01 | 1992-04-02 | Masanobu Yoshinaga | Cyclodextrin polymer and cyclodextrin membrane prepared using said polymer |
US5287850A (en) * | 1991-08-20 | 1994-02-22 | Habley Medical Technology Corporation | Timing and velocity controlled powered pharmaceutical inhaler |
JPH06100464A (en) * | 1992-06-08 | 1994-04-12 | Asahi Chem Ind Co Ltd | Composition of calcitonins for transpulmonary administration |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
DE4414128A1 (en) * | 1994-04-22 | 1995-10-26 | Consortium Elektrochem Ind | Partially acylated beta-cyclodextrins |
BE1008978A5 (en) * | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants for vaccines. |
-
1996
- 1996-11-01 US US08/740,778 patent/US5916883A/en not_active Expired - Lifetime
-
1997
- 1997-10-06 IL IL12965297A patent/IL129652A0/en unknown
- 1997-10-06 PT PT97910005T patent/PT935613E/en unknown
- 1997-10-06 ES ES97910005T patent/ES2176705T3/en not_active Expired - Lifetime
- 1997-10-06 CA CA002269519A patent/CA2269519C/en not_active Expired - Fee Related
- 1997-10-06 DK DK97910005T patent/DK0935613T3/en active
- 1997-10-06 NZ NZ335387A patent/NZ335387A/en unknown
- 1997-10-06 AU AU47483/97A patent/AU728398B2/en not_active Ceased
- 1997-10-06 DE DE69713369T patent/DE69713369T2/en not_active Expired - Fee Related
- 1997-10-06 EP EP97910005A patent/EP0935613B1/en not_active Expired - Lifetime
- 1997-10-06 WO PCT/US1997/018105 patent/WO1998020044A1/en active IP Right Grant
- 1997-10-06 JP JP52139498A patent/JP2001503802A/en not_active Ceased
- 1997-10-06 AT AT97910005T patent/ATE219109T1/en not_active IP Right Cessation
-
1999
- 1999-04-08 US US09/288,471 patent/US6204256B1/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3453260A (en) * | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclic anhydride esters of cyclodextrin |
US4670419A (en) * | 1982-07-28 | 1987-06-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its rectal use |
GB2145422A (en) * | 1983-08-26 | 1985-03-27 | Sandoz Ltd | Novel poly-esters, their preparation and pharmacological use thereof |
Non-Patent Citations (1)
Title |
---|
ZHONG-YAO SHEN ET AL.: "Synthesis and characterization of cyclomaltheptaose (Z)-2-butenedioic monoesters", CARBOHYDRATE RESEARCH, vol. 201, no. 2, 1 July 1990 (1990-07-01), AMSTERDAM, pages 241 - 247, XP000133952 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000026501A (en) * | 1998-07-10 | 2000-01-25 | Daicel Chem Ind Ltd | Acetylated nitrocellulose and its production |
US7786095B2 (en) | 2000-04-28 | 2010-08-31 | University College Dublin | Amphiphilic macrocyclic derivatives and their analogues |
WO2002080910A1 (en) * | 2001-04-10 | 2002-10-17 | Universidade Federal De Minas Gerais-Ufmg | Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
US7858597B2 (en) | 2001-04-10 | 2010-12-28 | Universidade Federal De Mimas Gerais - Ufmg | Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
Also Published As
Publication number | Publication date |
---|---|
US6204256B1 (en) | 2001-03-20 |
PT935613E (en) | 2002-11-29 |
US5916883A (en) | 1999-06-29 |
EP0935613B1 (en) | 2002-06-12 |
DE69713369D1 (en) | 2002-07-18 |
EP0935613A1 (en) | 1999-08-18 |
JP2001503802A (en) | 2001-03-21 |
AU4748397A (en) | 1998-05-29 |
AU728398B2 (en) | 2001-01-11 |
CA2269519A1 (en) | 1998-05-14 |
ES2176705T3 (en) | 2002-12-01 |
IL129652A0 (en) | 2000-02-29 |
ATE219109T1 (en) | 2002-06-15 |
DE69713369T2 (en) | 2003-02-13 |
DK0935613T3 (en) | 2002-10-07 |
NZ335387A (en) | 2001-05-25 |
CA2269519C (en) | 2007-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6204256B1 (en) | Acylated cyclodextrin derivatives | |
EP1906928B1 (en) | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture | |
US8535705B2 (en) | Biocompatible polymers and hydrogels and methods of use | |
US5821221A (en) | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides | |
JP5414023B2 (en) | Drug delivery device | |
JP2003518526A (en) | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) | |
JPS63502037A (en) | Biodegradable synthetic polypeptides and their therapeutic uses | |
US4835248A (en) | Biologically degradable polyamide for depot preparations having controlled release of the active compound | |
US8017152B2 (en) | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture | |
RU2202563C2 (en) | Phosphorylated polymers and their conjugates | |
KR20080039234A (en) | Hyaluronic acid and hydrophobic poly amino acid copolymer | |
JP2006506397A (en) | Solid and semi-solid polymer ion conjugates | |
MXPA99003959A (en) | Acylated cyclodextrin derivatives | |
KR100752702B1 (en) | Biodegradable polymer nanoparticles and method for preparing the same | |
EP1212095B1 (en) | Process to make a sustained release formulation | |
WO2007116965A1 (en) | Fine particle containing graft polymer and calcium compound | |
WO2003091283A1 (en) | Gelatin derivatives and high-molecular micelles comprising the same | |
US7605231B2 (en) | Gelatin derivatives and high-molecular micelle comprising the derivatives | |
MXPA04006982A (en) | Depot medicament, carrier materials for depot medicaments, and method for the production thereof. | |
IES61251B2 (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
JPH0640940A (en) | Fibroblast growth factor-stabilized composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2269519 Country of ref document: CA Ref country code: CA Ref document number: 2269519 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 335387 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/003959 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997910005 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 521394 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997910005 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997910005 Country of ref document: EP |